Morio Sawamura

1.7k total citations
86 papers, 1.0k citations indexed

About

Morio Sawamura is a scholar working on Hematology, Oncology and Molecular Biology. According to data from OpenAlex, Morio Sawamura has authored 86 papers receiving a total of 1.0k indexed citations (citations by other indexed papers that have themselves been cited), including 55 papers in Hematology, 38 papers in Oncology and 21 papers in Molecular Biology. Recurrent topics in Morio Sawamura's work include Multiple Myeloma Research and Treatments (39 papers), Lymphoma Diagnosis and Treatment (15 papers) and Chronic Lymphocytic Leukemia Research (14 papers). Morio Sawamura is often cited by papers focused on Multiple Myeloma Research and Treatments (39 papers), Lymphoma Diagnosis and Treatment (15 papers) and Chronic Lymphocytic Leukemia Research (14 papers). Morio Sawamura collaborates with scholars based in Japan, United States and Australia. Morio Sawamura's co-authors include Hirokazu Murakami, Jun‐ichi Tamura, Takuji Naruse, Takayuki Saitoh, T Matsushima, Jun Tsuchiya, Takafumi Matsushima, Kiyoshi Kubota, Tomohiko Tamura and Norifumi Tsukamoto and has published in prestigious journals such as SHILAP Revista de lepidopterología, Blood and British Journal of Haematology.

In The Last Decade

Morio Sawamura

83 papers receiving 1.0k citations

Peers

Countries citing papers authored by Morio Sawamura

Since Specialization

Citations

This map shows the geographic impact of Morio Sawamura's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Morio Sawamura with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Morio Sawamura more than expected).

Fields of papers citing papers by Morio Sawamura

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Morio Sawamura. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Morio Sawamura. The network helps show where Morio Sawamura may publish in the future.

Co-authorship network of co-authors of Morio Sawamura

This figure shows the co-authorship network connecting the top 25 collaborators of Morio Sawamura. A scholar is included among the top collaborators of Morio Sawamura based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Morio Sawamura. Morio Sawamura is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Evaluation of the Revised International Staging System (R-ISS) in Japanese patients with multiple myeloma 2019 ·Annals of Hematology ·Shuji Ozaki, Hiroshi Handa, Takayuki Saitoh, Hirokazu Murakami, (unknown), Hideki Asaoku, Kenshi Suzuki, Atsushi Isoda, Morio Matsumoto, Morio Sawamura, Kazutaka Sunami, Naoki Takezako, Shotaro Hagiwara, Yoshiaki Kuroda, Takaaki Chou, E Nagura, Kazuyuki Shimizu	9
2	Clinical characteristics and outcomes of diffuse large B-cell lymphoma in adolescents and young adults 2018 ·International Journal of Hematology ·Yasuhiro Suzuki, Takahiro Yano, Youko Suehiro, Hiromi Iwasaki, Michihiro Hidaka, Maki Otsuka, Kazutaka Sunami, (unknown), Morio Sawamura, Takuo Ito, Hiroatsu Iida, Hirokazu Nagai	5
3	Palonosetron, aprepitant, and dexamethasone for prevention of nausea and vomiting after high-dose melphalan in autologous transplantation for multiple myeloma: A phase II study 2016 ·International Journal of Hematology ·Atsushi Isoda, Rie Saito, (unknown), (unknown), (unknown), Tetsuya Ishikawa, Yuri Miyazawa, Morio Matsumoto, Morio Sawamura, (unknown)	11
4	Reduced frequency treatment with bortezomib plus dexamethasone for elderly patients with relapsed and/or refractory multiple myeloma: a phase 2 study of the Japanese Myeloma Study Group (JMSG-0902) 2016 ·Annals of Hematology ·Shuji Ozaki, Hiroyuki Hata, Masahiro Abe, Takayuki Saitoh, Ichiro Hanamura, Hiroki Yano, Kazutaka Sunami, Hiroshi Kosugi, Morio Sawamura, Tomonori Nakazato, Taro Masunari, Mayumi Mori, Toshiyuki Takagi, Hirokazu Murakami, Kazuyuki Shimizu	2
5	Silent venous thromboembolism in multiple myeloma patients treated with lenalidomide 2015 ·International Journal of Hematology ·Atsushi Isoda, (unknown), Yuri Miyazawa, (unknown), (unknown), (unknown), Morio Sawamura, Morio Matsumoto	4
6	Prognosis of mature T cell lymphoma is poorer than that of diffuse large B cell lymphoma in IPI low-risk group, but not in intermediate- and high-risk groups 2012 ·International Journal of Hematology ·Rika Kihara, Tomoyuki Watanabe, Takahiro Yano, Naokuni Uike, Seiichi Okamura, Fumio Kawano, Shuichi Hanada, Kazutaka Sunami, (unknown), Morio Sawamura, (unknown), Takeshi Shimomura, Kiyoshi Kitano, Yuki Kojima, Keizo Horibe, Hirokazu Nagai	6
7	Multi-center study on the prevalence of hypothyroidism in patients with hypercholesterolemia 2011 ·Endocrine Journal ·Tetsuya Tagami, Hironori Kimura, (unknown), Tsuyoshi Tanaka, Takashi Tanaka, (unknown), Miho Saito, Yasushi Miyazaki, Rika Araki, (unknown), Kazuya Yonezawa, Morio Sawamura, Ise T, Atsushi Ogo, Takuro Shimbo, Akira Shimatsu, Mitsuhide Naruse	29
8	Reduced risk of bacterial infection in multiple myeloma patients with VAD regimen without intermittent high-dose dexamethasone 2010 ·International Journal of Hematology ·Atsushi Isoda, Morio Matsumoto, Hirotaka Nakahashi, Momoko Mawatari, (unknown), Morio Sawamura	6
9	Phase II and pharmacokinetic study of thalidomide in Japanese patients with relapsed/refractory multiple myeloma 2009 ·International Journal of Hematology ·Hirokazu Murakami, Kazuyuki Shimizu, Morio Sawamura, Kenshi Suzuki, Isamu Sugiura, Hiroshi Kosugi, Chihiro Shimazaki, Masafumi Taniwaki, Masahiro Abe, Toshiyuki Takagi	9
10	A Pharmacokinetic Study Evaluating the Relationship Between Treatment Efficacy and Incidence of Adverse Events with Thalidomide Plasma Concentrations in Patients with Refractory Multiple Myeloma 2009 ·Clinical Lymphoma & Myeloma ·Tomoko Kodama, Masahiro Abe, Shinsuke Iida, Shuji Ozaki, Akira Sakai, Morio Sawamura, Chihiro Shimazaki, Akira Miyata, Toshio Wakayama, Hirokazu Murakami	8
11	Remission induction therapy containing rituximab markedly improved the outcome of untreated mature B cell lymphoma 2008 ·British Journal of Haematology ·Hirokazu Nagai, Takahiro Yano, Tomoyuki Watanabe, Naokuni Uike, Seiichi Okamura, Shuichi Hanada, Fumio Kawano, Kazutaka Sunami, (unknown), Morio Sawamura, Tetsuo Nishiura, Tomomitsu Hotta, Keizo Horibe	7
12	High Th1/Th2 ratio in patients with multiple myeloma 2004 ·Leukemia Research ·Hatsue Ogawara, Hiroshi Handa, Tohru Yamazaki, (unknown), (unknown), (unknown), (unknown), Yoriaki Kaneko, Takafumi Matsushima, Norifumi Tsukamoto, Yoshihisa Nojima, Morio Matsumoto, Morio Sawamura, Hirokazu Murakami	74
13	Clinical benefits of lenograstim in patients with neutropenia due to chemotherapy for multiple myeloma (MM) 2001 ·Supportive Care in Cancer ·Takeshi Takagi, Morio Sawamura, (unknown), M Kashimura, (unknown), T Hotta, N. Ogawa, K Hirashima	3
14	Risk factors for early death in patients undergoing treatment for multiple myeloma 2001 ·Annals of Hematology ·Hiroko Murakami, Kunihiko Hayashi, Nahoko Hatsumi, Tsuyoshi Saitoh, (unknown), T Matsushima, (unknown), Kimio Morita, (unknown), Hatsue Ogawara, Morio Sawamura, Yusuke Nojima	16
15	Primary nonsecretory plasma cell leukemia: a rare variant of multiple myeloma 1999 ·Annals of Hematology ·Etsuo Kawada, (unknown), Takayuki Saitoh, Jun‐ichi Tamura, (unknown), Morio Sawamura, Hirokazu Murakami	6
16	Tumour necrosis factor‐α and interleukin 4 promote the differentiation of myeloma cell precursors in multiple myeloma 1994 ·British Journal of Haematology ·Morio Sawamura, Hirokazu Murakami, Jun‐ichi Tamura, Takafumi Matsushima, Sadao Sato, Takuji Naruse, Jun Tsuchiya	8
17	Cyclic haemopoiesis at 7‐ or 8‐day intervals 1994 ·British Journal of Haematology ·Morio Sawamura, Sayuri Yamaguchi, Hirokazu Murakami, (unknown), Katsuhiko Itoh, Tadashi Maehara, Etsuo Kawada, Takafumi Matsushima, Jun‐ichi Tamura, Takuji Naruse, Jun Tsuchiya	4
18	Ultrastructure of plasma cells in a patient with J chain disease 1993 ·American Journal of Hematology ·Morio Sawamura, Hitoshi Kurabayashi, Hirokazu Murakami, Tohru Sakura, Jun‐ichi Tamura, Kazuo Kubota, Takuji Naruse, Jun Tsuchiya	4
19	MCNU in the treatment of essential thrombocythemia — a pilot study 1993 ·Annals of Hematology ·Hirokazu Murakami, Jun‐ichi Tamura, Morio Sawamura	4
20	Ultrastructure of multinucleated giant myeloma cells: Report of one case 1989 ·American Journal of Hematology ·Hitoshi Kurabayashi, Shuichi Miyawaki, Hirokazu Murakami, (unknown), Morio Sawamura, Kazuo Kubota, Takuji Naruse, Jun Tsuchiya	13

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact